Showing 6081-6090 of 9536 results for "".
- Valeant Unveils Advanced Deep Cleansing Duo for Acnehttps://practicaldermatology.com/news/20130730-valeant_unveils_advanced_deep_cleansing_duo_for_acne/2459487/Valeant Pharmaceuticals is has added additional products to its new AcneFree product line. Rounding out AcneFree's daily cleansing option are the AcneFree Advanced Cleansing Brush and AcneFree Oil-Free Purifying Cleanser. The Cleansing Brush features a two-speed rotating brush head to exfoliate and
- "What Not to Wear" Co-Host Partners with AbbVie on Psoriasis Campaignhttps://practicaldermatology.com/news/20130716-what_not_to_war_co-host_partners_with_abbvie_on_psoriasis_campaign/2459496/Stacy London, of TLC's "What Not to Wear," is partnering with AbbVie on a new psoriasis campaign called <a href="http://www.uncoveryourconfidence.com/">Uncover Your Confidence</a>. The campaign features educational resources and style advice for millions of Americans living with psoriasi
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- ExtendCredit Launches “Cosmetic Credit Plans”https://practicaldermatology.com/news/20130702-extendcredit_launches_cosmetic_credit_plans/2459505/“Cosmetic Credit Plans” is a fully automated, customizable in-house financing software solution created specifically for the cosmetic surgery industry, offered by ExtendCredit. The software enables cosmetic surgeons to offer their own financi
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- ASDS Launches Cosmetic Dermatology Fellowship Programhttps://practicaldermatology.com/news/20130627-asds_launches_cosmetic_dermatology_fellowship_program/2459508/The American Society for Dermatologic Surgery (ASDS) launched a fellowship accreditation program designed to promote post-residency training in cosmetic dermatologic surgery procedures. According to ASDS President Timothy C. Flynn, MD, fellowship training will give young dermatologists a solid educa
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests t